Table 3.
DNA Repair Gene Polymorphisms and Patient Survival in relation to Subtypes.
| Genotype | Patients n | MST (mon) | Log-rank p value | HR (95% CI) | Adjusted HR | ||
|---|---|---|---|---|---|---|---|
|
| |||||||
| p value | (95% CI) a | p value | |||||
| Adenocarcinoma | |||||||
| OGG1 | |||||||
| Ser/Ser | 16 | 62 | - | 1.00 | - | 1.00 | - |
| Ser/Cys, Cys/Cys | 49 | 68 | 0.784 | 0.89 (0.38–2.08) | 0.785 | 0.80 (0.29–2.26) | 0.803 |
| MUTYH | |||||||
| Gln/Gln | 13 | 70 | 1.00 | 1.00 | |||
| Gln/His, His/His | 52 | 66 | 0.65 | 1.25 (0.48–3.27) | 0.653 | 1.54 (0.44–5.36) | 0.498 |
| APEX | |||||||
| Asp/Asp | 28 | 63 | - | 1.00 | - | 1.00 | - |
| Asp/Glu, Glu/Glu | 37 | 70 | 0.549 | 0.80 (0.39–1.67) | 0.553 | 1.14 (0.48–2.73) | 0.763 |
| XRCC1 | |||||||
| Arg/Arg | 26 | 71 | 1.00 | - | 1.00 | - | |
| Arg/Gln, Gln/Gln | 39 | 64 | 0.522 | 1.28 (0.60–2.76) | 0.526 | 0.87 (0.35–2.20) | 0.775 |
| XRCC3 | |||||||
| Thr/Thr | 58 | 67 | - | 1.00 | - | 1.00 | - |
| Thr/Met, Met/Met | 7 | 64 | 0.995 | 1.00 (0.30–3.32) | 0.995 | 1.32 (0.38–4.64) | 0.661 |
| Squamous Cell Carcinoma | |||||||
| OGG1 | |||||||
| Ser/Ser | 8 | 52 | - | 1.00 | - | 1.00 | - |
| Ser/Cys, Cys/Cys | 21 | 48 | 0.824 | 1.11 (0.43–2.88) | 0.825 | 1.25 (0.44–3.55) | 0.670 |
| MUTYH | |||||||
| Gln/Gln | 5 | 64 | - | 1.00 | - | 1.00 | - |
| Gln/His, His/His | 24 | 45 | 0.377 | 1.72 (0.51–5.85) | 0.385 | 4.73 (0.51–5.85) | 0.153 |
| APEX | |||||||
| Asp/Asp | 11 | 40 | 1.00 | - | 1.00 | - | |
| Asp/Glu, Glu/Glu | 18 | 54 | 0.328 | 0.65 (0.27–1.56) | 0.334 | 0.43 (0.14–1.32) | 0.139 |
| XRCC1 | |||||||
| Arg/Arg | 16 | 50 | 1.00 | - | 1.00 | - | |
| Arg/Gln, Gln/Gln | 13 | 46 | 0.991 | 1.00 (0.42–2.37) | 0.991 | 1.17 (0.46–2.94) | 0.743 |
| XRCC3 | |||||||
| Thr/Thr | 25 | 48 | - | 1.00 | - | 1.00 | - |
| Thr/Met, Met/Met | 4 | 13 | <0.0001 | 9.35 (2.52–34.68) | 0.001 | 9.05 (1.89–44.39) | 0.006 |
a
HR adjusted for gender, age, smoking history, disease stage, metastasis, and reccurence.